CNSP Company Profile and Key Details

CNSP has shown mixed momentum, gaining 20.97% over the past week and -20.98% over the past quarter, though year-to-date performance is up 38.48%. Short-term trend indicators are bullishly aligned (SMA20 -23.77%, SMA50 -42.41%, SMA200 -61.59%). The stock’s 14-day RSI is 22.3 (weak momentum), while the ATR of 0.4 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -94.44% below its high and over 4.07% above its low. Average 10-day trading volume of 16.64 million shares is significantly above the 3-month average of 1.54 million, indicating heightened recent market interest.

CNS Pharmaceuticals, Inc. generated EPS of -$58.07 over the past year. Five-year average earnings growth is 70.59%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $20.00. The high target offers 155.1% upside. The low target suggests 155.1% downside. The mean target is $20.00. This offers 155.1% upside. CNS Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended March 31, 2026, missed forecasts by 89.01%. The prior quarter beat by -13.12%. Over the last six quarters, Apple has recorded several small beats. These include 12.5% in May 15, 2024.

CNS Pharmaceuticals, Inc. has 574.58 thousand shares outstanding. The public float is 525.99 thousand shares, elevated short interest at 11.06% of float. This equals 63.57 thousand shares. The short ratio is 0.88 days. Institutional investors hold 7.45% of the float. Insiders own 0.17%. Climaco John M holds 215.68 thousand shares, Priebe Waldemar has 156.81 thousand shares and Downs Christopher has 103.44 thousand shares.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) closed at $7.84 USD, gaining $5.53 (239.39%) from the previous close of $2.31. The stock is currently mid-range between its 52-week high and low $1.90 and $34.80. With a market capitalization of about $4.50 million, CNS Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.54). Key stats such as the average daily volume over the past year has been around 1.42 million shares, trading with heavier-than-usual volume. Headquartered in Houston, TX, CNS Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Rami Levin, the company employs approximately 4 people and listed since November 08, 2019. CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.

CNS Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $15.50. This means the shares are trading below this model’s fair value.

CNS Pharmaceuticals, Inc. trades at a P/E ratio of -0.21, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.75 suggesting the stock is closer to book value. The P/FCF stands at -0.32, also above market averages.

Our AI price prediction model suggests that CNS Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.13%, with price expected at $7.83 by May 18, 2026, within a range of $7.56 to $8.12 3-Month Outlook: Projected fall of -12.5%, reaching $6.86 by July 31, 2026, with a range of $5.37 to $8.49. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by May 04, 2027, within a range of $0.00 to $864.31.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) shares are up 38.48% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows CNS Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.50, suggesting 97.7% upside. Our AI forecast model points to short-term weakness (-0.13% over two weeks), a medium-term fall (-12.5% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.